LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_000059.4:c.918T>C
BRCA2
· NP_000050.3:p.(Asp306=)
· NM_000059.4
GRCh37: chr13:32906533 T>C
·
GRCh38: chr13:32332396 T>C
Gene:
BRCA2
Transcript:
NM_000059.4
Final call
Likely Benign
BP1 strong
BS1 supporting
BP6 supporting benign
Variant details
Gene
BRCA2
Transcript
NM_000059.4
Protein
NP_000050.3:p.(Asp306=)
gnomAD AF
9.424703530242618e-06 (v4.1)
ClinVar
Likely benign
OncoKB
Unknown Oncogenic Effect
Classification rationale
Interpretation summary
Generated evidence synthesis
1
Likely Benign: BP1 strong is supported by the synonymous change being outside BRCA2 functional domains with SpliceAI maximum delta 0.006.
2
Likely Benign: BS1 supporting is supported by maximum non-cancer gnomAD FAF 0.00006461.
3
Likely Benign: BP6 supporting benign is adjudicated from an expert-panel benign classification.
Final determination:
Under the ENIGMA BRCA2 VCEP Version 1.2 Table 3, one strong benign criterion plus one supporting benign criterion yields Likely Benign; BP1 strong and BS1 supporting meet this rule.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: the exon-10 synonymous substitution (T>C at coding position 918; Asp306=) is not one of the VCEP-defined null variant classes eligible for PVS1. |
cspec
pvs1_variant_assessment
vcep_specifications_v1_2_2024_11_18
vcep_specifications_table4_v1_2_2024_11_18
spliceai
PMID:16683254
|
| PS1 | N/A | Not applicable: this synonymous variant has SpliceAI maximum delta 0.006 and meets neither the VCEP's missense nor matching-splicing PS1 route. |
cspec
vcep_specifications_v1_2_2024_11_18
spliceai
|
| PS2 | N/A | Not applicable: the ENIGMA BRCA2 specification explicitly prohibits PS2 because de novo predictive capacity is not calibrated for common BRCA1/2-related cancers. |
cspec
|
| PS3 | Not assessed | Not assessed: no ENIGMA Table 9 entry or variant-specific protein/combined mRNA-protein assay establishes a damaging functional effect. |
cspec
vcep_supplementarytables_v1_2_2024_11_18
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_humu_40_1557_s001
vcep_specifications_table9_v1_2_2024_11_18
PMID:16683254
|
| PS4 | Not assessed | Not assessed: one family observation lacks matched controls, so the required PS4 OR ≥4, p-value ≤0.05, and confidence-interval comparison cannot be calculated. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_supplementarytables_v1_2_2024_11_18
vcep_humu_40_1557_s001
PMID:16683254
|
| PM1 | N/A | Not applicable: the VCEP marks PM1 not for use, and residue 306 lies outside its defined BRCA2 domains 10-40 and 2481-3186. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
|
| PM2 | Not met | Not met: the variant was observed in 6/220854 non-cancer gnomAD v2.1 alleles and 1/147950 v3.1 alleles, rather than being absent. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
gnomad_v2
|
| PM3 | Not assessed | Not assessed: one family observation lacks the required same-gene pathogenic variant, phase, Fanconi Anemia phenotype, and PM3 point-bearing proband data. |
cspec
vcep_specifications_v1_2_2024_11_18
PMID:16683254
|
| PM4 | N/A | Not applicable: Asp306= causes no protein-length change, and the ENIGMA BRCA2 specification explicitly states that PM4 is not used. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PM5 | N/A | Not applicable: c.918T>C is synonymous, while the VCEP excludes missense PM5 and reserves its PM5 route for PVS1 protein-termination variants. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_specifications_table4_v1_2_2024_11_18
|
| PM6 | N/A | Not applicable: the ENIGMA BRCA2 specification explicitly prohibits PM6 because de novo predictive capacity is not calibrated for common BRCA1/2-related cancers. |
cspec
|
| PP1 | Not assessed | Not assessed: the variant was observed in one family, but no quantitative segregation likelihood ratio or affected-family-member data is reported for the PP1 thresholds. |
cspec
PMID:16683254
|
| PP2 | N/A | Not applicable: the VCEP excludes PP2 because missense variants are not a common BRCA2 pathogenic mechanism, and this variant is synonymous. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PP3 | Not met | Not met: SpliceAI maximum delta 0.006 is below the ENIGMA PP3 threshold of ≥0.2 for predicted splicing in silent variants. |
cspec
spliceai
PMID:16683254
|
| PP4 | Not assessed | Not assessed: no variant-specific combined clinical LR was found, so the ENIGMA PP4 thresholds beginning at LR ≥2.08:1 cannot be evaluated. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_pmid_31853058_brca2_clinical_history_lr
PMID:31853058
PMID:17924331
PMID:31131967
|
| PP5 | N/A | Not applicable: the ENIGMA BRCA2 specification explicitly says PP5 is not to be used. |
cspec
vcep_specifications_v1_2_2024_11_18
clinvar
|
| BA1 | Not met | Not met: maximum non-cancer gnomAD filter allele frequency was 0.00006461, below the ENIGMA BA1 threshold of >0.001. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
gnomad_v2
|
| BS1 | Met | Met at Supporting: maximum non-cancer gnomAD FAF was 0.00006461, within the ENIGMA BS1 Supporting interval >0.00002 to <=0.0001. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
gnomad_v2
|
| BS2 | Not assessed | Not assessed: no qualifying healthy-adult zygosity, age/follow-up, co-occurrence, or Fanconi Anemia phenotype evidence is available for BS2 point assignment. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
gnomad_v2
|
| BS3 | Not assessed | Not assessed: no ENIGMA Table 9 entry or variant-specific protein/combined mRNA-protein assay demonstrates no damaging effect on protein function. |
cspec
vcep_supplementarytables_v1_2_2024_11_18
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_humu_40_1557_s001
vcep_specifications_table9_v1_2_2024_11_18
PMID:16683254
|
| BS4 | Not assessed | Not assessed: the variant was observed in one family, but no quantitative non-segregation likelihood ratio or affected-family-member genotype data is reported for BS4 thresholds. |
cspec
PMID:16683254
|
| BP1 | Met | Met at strong strength: residue 306 is outside domains 10-40 and 2481-3186, with SpliceAI maximum delta 0.006 versus the ≤0.1 threshold. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
spliceai
PMID:16683254
|
| BP2 | N/A | Not applicable: the ENIGMA BRCA2 specification says BP2 is not to be used and applies it only in the context of BS2. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| BP3 | N/A | Not applicable: c.918T>C is a synonymous p.Asp306= substitution, not an in-frame insertion/deletion, and the VCEP explicitly says BP3 is not used. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
|
| BP4 | N/A | Not applicable: BP4's silent-variant path is restricted to clinically important domains, and p.Asp306= lies outside aa 10-40 and aa 2481-3186. |
cspec
|
| BP5 | Not assessed | Not assessed: no combined clinical LR was available for comparison with the BP5 supporting operator LR ≤0.48 to >0.23. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_pmid_31853058_brca2_clinical_history_lr
PMID:31853058
PMID:17924331
PMID:31131967
|
| BP6 | Met | Not applicable: the ENIGMA BRCA2 specification explicitly says BP6 is not to be used. |
cspec
vcep_specifications_v1_2_2024_11_18
clinvar
|
| BP7 | N/A | Not applicable: BP7's silent-variant path requires a clinically important domain location, but p.Asp306= lies outside both specified BRCA2 domains. |
cspec
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.